Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 3
2019 2
2020 1
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART).
Bryant JM, Palm RF, Herrera R, Rubens M, Hoffe SE, Kim DW, Kaiser A, Ucar A, Fleming J, De Zarraga F, Hodul P, Aparo S, Asbun H, Malafa M, Jimenez R, Denbo J, Frakes JM, Chuong MD. Bryant JM, et al. Among authors: aparo s. Cancer Control. 2023 Jan-Dec;30:10732748221150228. doi: 10.1177/10732748221150228. Cancer Control. 2023. PMID: 36598464 Free PMC article.
Causes of Death Among Patients With Initially Inoperable Pancreas Cancer After Induction Chemotherapy and Ablative 5-fraction Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy.
Chuong MD, Herrera R, Ucar A, Aparo S, De Zarraga F, Asbun H, Jimenez R, Asbun D, Narayanan G, Joseph S, Kotecha R, Hall MD, Mittauer KM, Alvarez D, McCulloch J, Romaguera T, Gutierrez A, Kaiser A. Chuong MD, et al. Among authors: aparo s. Adv Radiat Oncol. 2022 Sep 25;8(1):101084. doi: 10.1016/j.adro.2022.101084. eCollection 2023 Jan-Feb. Adv Radiat Oncol. 2022. PMID: 36483070 Free PMC article.
Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma.
Acuna-Villaorduna A, Shankar V, Wysota M, Jirgal A, Kabarriti R, Bellemare S, Goldman I, Kaubisch A, Aparo S, Goel S, Chuy J. Acuna-Villaorduna A, et al. Among authors: aparo s. Cancer Control. 2022 Jan-Dec;29:10732748221134411. doi: 10.1177/10732748221134411. Cancer Control. 2022. PMID: 36221952 Free PMC article. Clinical Trial.
Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer.
Chuong MD, Herrera R, Kaiser A, Rubens M, Romaguera T, Alvarez D, Kotecha R, Hall MD, McCulloch J, Ucar A, DeZarraga F, Aparo S, Joseph S, Asbun H, Jimenez R, Narayanan G, Gutierrez AN, Mittauer KE. Chuong MD, et al. Among authors: aparo s. Front Oncol. 2022 Jun 23;12:888462. doi: 10.3389/fonc.2022.888462. eCollection 2022. Front Oncol. 2022. PMID: 35814383 Free PMC article.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Doki Y, et al. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. N Engl J Med. 2022. PMID: 35108470 Clinical Trial.
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin.
Rao D, Mallick AB, Augustine T, Daroqui C, Jiffry J, Merla A, Chaudhary I, Seetharam R, Sood A, Gajavelli S, Aparo S, Rajdev L, Kaubisch A, Chuy J, Negassa A, Mariadason JM, Maitra R, Goel S. Rao D, et al. Among authors: aparo s. Oncotarget. 2019 Sep 17;10(53):5510-5522. doi: 10.18632/oncotarget.27140. eCollection 2019 Sep 17. Oncotarget. 2019. PMID: 31565185 Free PMC article.
21 results